BACKGROUND:Children born to women with low thyroid hormone levels have been reported to have decreased cognitive function. METHODS: We conducted a randomized trial in which pregnant women at a gestation of 15 weeks 6 days or less provided blood samples for measurement of thyrotropin and free thyroxine (T(4)). Women were assigned to a screening group (in which measurements were obtained immediately) or a control group (in which serum was stored and measurements were obtained shortly after delivery). Thyrotropin levels above the 97.5th percentile, free T(4) levels below the 2.5th percentile, or both were considered a positive screening result. Women with positive findings in the screening group were assigned to 150 μg of levothyroxine per day. The primary outcome was IQ at 3 years of age in children of women with positive results, as measured by psychologists who were unaware of the group assignments. RESULTS: Of 21,846 women who provided blood samples (at a median gestational age of 12 weeks 3 days), 390 women in the screening group and 404 in the control group tested positive. The median gestational age at the start of levothyroxine treatment was 13 weeks 3 days; treatment was adjusted as needed to achieve a target thyrotropin level of 0.1 to 1.0 mIU per liter. Among the children of women with positive results, the mean IQ scores were 99.2 and 100.0 in the screening and control groups, respectively (difference, 0.8; 95% confidence interval [CI], -1.1 to 2.6; P=0.40 by intention-to-treat analysis); the proportions of children with an IQ of less than 85 were 12.1% in the screening group and 14.1% in the control group (difference, 2.1 percentage points; 95% CI, -2.6 to 6.7; P=0.39). An on-treatment analysis showed similar results. CONCLUSIONS: Antenatal screening (at a median gestational age of 12 weeks 3 days) and maternal treatment for hypothyroidism did not result in improved cognitive function in children at 3 years of age. (Funded by the Wellcome Trust UK and Compagnia di San Paulo, Turin; Current Controlled Trials number, ISRCTN46178175.).
RCT Entities:
BACKGROUND:Children born to women with low thyroid hormone levels have been reported to have decreased cognitive function. METHODS: We conducted a randomized trial in which pregnant women at a gestation of 15 weeks 6 days or less provided blood samples for measurement of thyrotropin and free thyroxine (T(4)). Women were assigned to a screening group (in which measurements were obtained immediately) or a control group (in which serum was stored and measurements were obtained shortly after delivery). Thyrotropin levels above the 97.5th percentile, free T(4) levels below the 2.5th percentile, or both were considered a positive screening result. Women with positive findings in the screening group were assigned to 150 μg of levothyroxine per day. The primary outcome was IQ at 3 years of age in children of women with positive results, as measured by psychologists who were unaware of the group assignments. RESULTS: Of 21,846 women who provided blood samples (at a median gestational age of 12 weeks 3 days), 390 women in the screening group and 404 in the control group tested positive. The median gestational age at the start of levothyroxine treatment was 13 weeks 3 days; treatment was adjusted as needed to achieve a target thyrotropin level of 0.1 to 1.0 mIU per liter. Among the children of women with positive results, the mean IQ scores were 99.2 and 100.0 in the screening and control groups, respectively (difference, 0.8; 95% confidence interval [CI], -1.1 to 2.6; P=0.40 by intention-to-treat analysis); the proportions of children with an IQ of less than 85 were 12.1% in the screening group and 14.1% in the control group (difference, 2.1 percentage points; 95% CI, -2.6 to 6.7; P=0.39). An on-treatment analysis showed similar results. CONCLUSIONS: Antenatal screening (at a median gestational age of 12 weeks 3 days) and maternal treatment for hypothyroidism did not result in improved cognitive function in children at 3 years of age. (Funded by the Wellcome Trust UK and Compagnia di San Paulo, Turin; Current Controlled Trials number, ISRCTN46178175.).
Authors: Jens Henrichs; Jacoba J Bongers-Schokking; Jacqueline J Schenk; Akhgar Ghassabian; Henk G Schmidt; Theo J Visser; Herbert Hooijkaas; Sabine M P F de Muinck Keizer-Schrama; Albert Hofman; Vincent V W Jaddoe; Willy Visser; Eric A P Steegers; Frank C Verhulst; Yolanda B de Rijke; Henning Tiemeier Journal: J Clin Endocrinol Metab Date: 2010-06-09 Impact factor: 5.958
Authors: V J Pop; J L Kuijpens; A L van Baar; G Verkerk; M M van Son; J J de Vijlder; T Vulsma; W M Wiersinga; H A Drexhage; H L Vader Journal: Clin Endocrinol (Oxf) Date: 1999-02 Impact factor: 3.478
Authors: Akhgar Ghassabian; Jacoba J Bongers-Schokking; Jens Henrichs; Vincent W V Jaddoe; Theo J Visser; Willy Visser; Sabine M P F de Muinck Keizer-Schrama; Herbert Hooijkaas; Eric A P Steegers; Albert Hofman; Frank C Verhulst; Jan van der Ende; Yolanda B de Rijke; Henning Tiemeier Journal: Pediatr Res Date: 2011-05 Impact factor: 3.756
Authors: Victor J Pop; Evelien P Brouwers; Huib L Vader; Thomas Vulsma; Anneloes L van Baar; Jan J de Vijlder Journal: Clin Endocrinol (Oxf) Date: 2003-09 Impact factor: 3.478
Authors: Gabriella Morreale de Escobar; María Jesús Obregón; Francisco Escobar del Rey Journal: Best Pract Res Clin Endocrinol Metab Date: 2004-06 Impact factor: 4.690
Authors: M Altomare; S La Vignera; P Asero; D Recupero; R A Condorelli; P Scollo; A Gulisano; E Magro; D Tumino; S Tumino; E Vicari; V Leanza; R D'Agata; A E Calogero Journal: J Endocrinol Invest Date: 2012-10-22 Impact factor: 4.256